GlassScriptPhysician profile
Tarisha R Mixon
NPI 1982915195
$2,909.05
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.49 · 2020: $138 · 2021: $295 · 2022: $647 · 2023: $876 · 2024: $564 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.82 | 2021-2025 | |
| Glaxosmithkline, LLC. | $461.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $315.84 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $186.54 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $177.75 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $166.97 | 2022-2023 | Hetlioz |
| Lilly USA, LLC | $164.39 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Fujifilm Healthcare Americas Corporation | $100.33 | 2023 | Utaswako Afp-L3 |
| Otsuka America Pharmaceutical, INC. | $93.93 | 2022-2025 | Rexulti, Abilify Maintena |
| Amarin Pharma, INC. | $68.13 | 2019-2021 | |
| Novo Nordisk INC | $65.51 | 2020-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.55 | 2020-2025 | Jardiance |
| Dexcom, INC. | $56.47 | 2021-2024 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $55.86 | 2025 | Ibsrela |
| Pfizer INC. | $52.76 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $46.32 | 2019-2023 | Trintellix |
| Lundbeck LLC | $44.63 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $39.65 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.37 | 2024 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $32.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.02 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $18.84 | 2024 | |
| Exact Sciences Corporation | $15.06 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarisha Mixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.